China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop antibody drug conjugates (ADCs) leveraging Escugen’s linker-payload technology, EZWi Fit, and Foreseen’s first-in-class antibodies and targets. This collaboration aims to create ADCs with enhanced drug efficacy and resistance in various tumor models, offering differentiated clinical indications and development pathways.
Preliminary Research Results and Multinational Interest
Preliminary collaborative research results have shown that their first co-developed ADC molecule exhibits significant advantages in drug efficacy and resistance. The RMB 5 billion (USD 700 million) deal has piqued the interest of multiple multinational companies for overseas rights, highlighting the potential global impact of this partnership.
Escugen’s Continued Focus on ADC Development
Previously, in April of this year, Escugen teamed up with Tot Biopharmaceutical International Co., Ltd (HKG: 1875) to delve into the research, development, and manufacturing of ADCs. Under that agreement, Tot Bio provided manufacturing and related services to support Escugen’s ADC programs and global development plans, further solidifying Escugen’s commitment to advancing ADC technology.- Flcube.com
